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SPECIFIC AIMS
In the present study we aimed to identify novel P-
selectin antagonists that would inhibit leukocyte attach-
ment and rolling in vitro and have potent anti-inflam-
matory effects in vivo in a murine model of allergic
airway disease.
PRINCIPAL FINDINGS
1. Potent P-selectin antagonists were designed based
on a polymerized lipid nanoparticle (PLNP) that
displays ligand mimetics simulating PSGL-1. The
inhibitors specifically blocked P-selectin-dependent
attachment and rolling of leukocytes in vitro
The novel inhibitors display only the key elements of
PSGL-1 responsible for adhesion to P-selectin; there-
fore, all but the key carbohydrate unit fucose were
removed from the sialyl Lewis X (sLex) carbohydrate.
This carbohydrate was displayed along with polyvalent
sulfate ester groups to emulate the sLex/sulfated ty-
rosine super ligand motif shown to be critical for
P-selectin binding. Nanoparticle formulations were
tested in which the ratio of fucose, sulfate, and polyeth-
ylene glycol were varied. The optimal ratio of the four
lipids was found to be fucose:sulfate:PEG:matrix 5:25:
1:69. The efficacy of formulation changes were evalu-
ated in an in vitro recirculating loop assay (Proteo-
Flow) in which interactions between PSGL-1-
expressing human leukocytes (U-937) and P-selectin-
coated glass capillary surfaces at physiological shear
rates were monitored. In the absence of PLNP, the
number of U-937 cells interacting with the coated
capillary tubes gradually increased with time. Adminis-
tration of PLNP after establishing the leukocyte/selec-
tin rolling interaction reversed the existing rolling, and
completely inhibited new cell attachment (Fig. 1a). By
increasing the PEG lipid level from 1% to 15%, selectin
inhibitory activity of the PLNP was abolished (Fig. 1a),
providing a nanoparticle that could be used as a
negative control PLNP in other experiments. The leu-
kocyte/P-selectin inhibition activity of the PLNP
showed a dose-dependent decrease (Fig. 1b), with no
effect on leukocyte/E-selectin interactions (Fig. 1c).
2. After intravenous administration of selectin PLNP
antagonists in a murine endotoxin model of systemic
activation, PLNP binding was almost exclusively
restricted to endothelial cells within the lung. The
absence of PLNP binding in E/P-selectin / mice
confirmed that this pattern of distribution was
consistent with selectin-specific attachment of the
inhibitor to the endothelium
After identifying potent PLNP inhibitors in vitro, their
ability to bind preferentially to selectins on activated
endothelial cells was confirmed in vivo. Wild-type
C57Bl6 (WT) mice and mice deficient in E- and P-
selectin (E/P/) expression were injected with i.v.
LPS, then PLNP 2 h later. Tissue samples were col-
lected for histological analysis 3 h after PLNP injection
and the distribution of autofluorescent PLNP was ex-
amined in the lung. In the absence of LPS, few PLNPs
were found in contact with the endothelium in WT
mice. After LPS treatment, extensive PLNP binding was
visible mainly on the endothelial cells within the lung
vasculature. In E/P/ mice stimulated with LPS, there
was little or no direct binding of the PLNP to the
endothelial cells although some PLNPs were associated
with a small number of leukocytes.
3. A single administration of selectin PLNP in a
murine model of allergic airway disease led to
prolonged attachment of PLNP to the surface of
endothelial cells after allergen challenge, resulting
in a reduction in the level of allergen-induced
peribronchial inflammation and airway
hyper-responsiveness in the lungs
The in vivo efficacy of the selectin PLNP was assessed in
a selectin-dependent murine model of cockroach aller-
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gen(CRA)-induced allergic airway inflammation. Selec-
tin PLNPs administered 2 h after allergen challenge
were still visible on the endothelial cell surface almost
24 h later. These PLNPs were also seen in association
with the alveolar walls but were not present in large
airways. Negative control PLNPs were not detected in
association with leukocytes or endothelial cells within
the lung vasculature. Treatment with selectin PLNP
altered the responses in CRA-induced lung inflamma-
tion compared with mice treated with control PLNP or
allergen alone. Methacholine-induced airway hyper-
responsiveness and peribronchial inflammation (Fig.
2) were both significantly reduced in mice treated with
P-selectin-specific PLNP compared with those treated
with CRA alone or control PLNP.
CONCLUSIONS AND SIGNIFICANCE
Some studies have identified selectins as potential
targets for the design of novel anti-inflammatory
agents, and research has focused on identifying the
structural features required for high selectin binding
affinity. Therapeutically viable P-selectin inhibitors
have proved difficult to realize due to the weak binding
of the monovalent ligands and high cost of producing
physiological ligand-based inhibitors such as sLex or
PSGL-1. Identification of critical interactions that occur
between P-selectin and the physiologic ligand PSGL-1
served as a starting point for the design of our inhibitor.
Although as an unmodified monosaccharide fucose has
no reported P-selectin blocking activity, some sulfated
carbohydrates and sulfated fuco-oligosaccharides do
show inhibition. If fucose and sulfate could be pre-
sented to P-selectin in the proper orientation on a
synthetic carrier, a relatively simple inhibitor could be
designed. We and others have demonstrated that poly-
valent display of fucose or fucosylated oligosaccharides
in proximity to multiple sulfate ester groups creates a
potent inhibitor for P-selectin-mediated adhesion. Our
PLNPs display fucose and sulfate groups on a macro-
molecular structure created by mixing lipids with these
molecules to direct self-assembly into liposome bilayers.
Design of new selectin inhibitors has been hampered
by the lack of high-throughput physiologic assays that
rigorously measure the potency of potential inhibitors
Figure 1. Inhibition of P-selectin-
but not E-selectin-mediated leuko-
cyte cell tethering/rolling by PLNP
under shear in vitro. Selectin-
blocking PLNPs (1% PEG) or neg-
ative control PLNPs (15% PEG)
were administered after U-937 cell
rolling was established on P-selec-
tin-coated capillary tubes and the
number of cells interacting with
the wall of the capillary tube was
determined (a). Rolling of U937
cells was established on P-selectin
chimera-coated capillary tubes and
the dose-dependent effect of P-se-
lectin blocking PLNP was deter-
mined (b). Comparison of the in-
hibitory effect of selectin-blocking
PLNP on U-937 interactions with P-
or E-selectin chimera-coated capil-
lary tubes (c). All data are represen-
tative of 3–4 independent experi-
ments showing similar results.
Figure 2. Inhibition of peribronchial eosinophil recruitment
by selectin PLNP. The number of peribronchial eosinophils
was determined in 50 high-power fields from H&E-stained
lung sections (1000). Data are representative of 3 indepen-
dent experiments and expressed as mean  se (n5–6 mice
per group).
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under conditions that truly mimic blood flow. Many
reported selectin inhibitors have typically been assayed
under static conditions. While this may provide a
starting point from which to design inhibitors, the
inhibition measured under static conditions with this
type of adhesion protein can be irrelevant when sub-
jected to shear forces.
To simulate the microenvironment a drug and leu-
kocyte would experience in vivo, we used an in vitro
system where the luminal surfaces of capillary tubes
were coated with P-selectin proteins. The "vessels" are
integrated into a loop system in which fluid can be
recirculated via a peristaltic pump. PSGL-1-expressing
U-937 cells were injected into the system and their
interaction with the protein monolayer was monitored
by video microscopy. Potential P-selectin inhibitors are
infused into the assay and their effect on leukocyte/
protein interactions is readily measured. We have dem-
onstrated that the PLNPs are targeted primarily to
P-selectin on the endothelium and preferentially in-
hibit established P-selectin- but not E-selectin-depen-
dent leukocyte rolling/attachment in vitro.
Our studies indicated that binding of nanoparticles
to the endothelium was selectin-specific in both LPS-
and CRA-induced inflammation and that the PLNPs
remain in contact with the endothelium, acting as
inhibitors of selectin-mediated leukocyte attachment
and rolling over a prolonged period. The severity of
allergic airway disease is primarily dependent on the
extent of the inflammatory response, and attenuation
of leukocyte infiltration in the lung is frequently corre-
lated with clinical improvement. Studies of selectin
involvement in the pathogenesis of allergic airway
disease have identified a key role for E- and P-selectin;
therefore, the efficacy of our selectin antagonists was
tested in a murine model of this disease. P-selectin-
specific PLNP significantly attenuated methacholine-
induced airway hyper-responsiveness and peribronchial
eosinophilia 24 h after allergen challenge. At 24 h,
PLNP could still be identified in association with the
endothelial cell surface in the lung vasculature, and it is
conceivable that a single administration of PLNP may
inhibit leukocyte recruitment for much longer.
In summary, these studies demonstrate the discovery
of a P-selectin inhibitor with potent in vivo activity by
using a physiologically relevant in vitro shear assay
system. The use of novel glycomimetics to specifically
deliver sterically inhibitory P-selectin binding nanopar-
ticles to the endothelium may have therapeutic poten-
tial for allergy/asthma as well as other inflammatory
diseases.
Figure 3. Inhibition of eosinophil recruitment by
selectin-targeted nanoparticles. Eosinophil recruit-
ment to peribronchial areas of the lung plays an
important role in mediating airway hyper-respon-
siveness in allergic airway disease. Extravasation of
eosinophils from the vasculature to the airways is
preceded by P-selectin-mediated attachment and
rolling of leukocytes on the endothelial cell sur-
face. Inhibition of these processes by the binding
of PLNP to P-selectin prevents the subsequent
integrin-mediated firm adhesion of eosinophils to
the endothelium, a prerequisite step for migration
through the blood vessel wall and toward the
airways.
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